Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Coeur Commences Drilling at Silver North's Tim Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Mast Therapeutics MSTX

Healthcare Biotechnology
"Mast Therapeutics Inc is a biopharmaceutical company developing clinical-stage therapies for serious or life-threatening diseases with significant unmet needs. Its product candidate, AIR001, a sodium nitrite solution for inhalation via nebulization."

Recent & Breaking News (NYSEAM:MSTX)

Mast Announces Presentation Of Results Of Nonclinical Study Of Vepoloxamer In Chronic Heart Failure At The HFSA's Annual Scientific Meeting

PR Newswire September 28, 2015

Mast Therapeutics To Host Analyst & Investor Day On October 7, 2015

PR Newswire September 23, 2015

Mast Therapeutics Reports Second Quarter 2015 Financial Results

PR Newswire August 12, 2015

Mast Therapeutics To Host Second Quarter 2015 Financial Results And Corporate Update Conference Call

PR Newswire August 6, 2015

Mast Therapeutics Announces Change In Board Of Directors

PR Newswire May 28, 2015

Mast Therapeutics Announces Initiation Of EPIC-E Study

PR Newswire May 26, 2015

Mast Therapeutics Reports First Quarter 2015 Financial Results

PR Newswire May 11, 2015

Enrollment In Mast Therapeutics' Phase 3 "EPIC" Study In Sickle Cell Disease Surpasses Halfway Mark

PR Newswire April 21, 2015

Mast To Present New Data Supporting Vepoloxamer (MST-188) In Sickle Cell Disease At 9th Annual Sickle Cell Disease Research And Education Symposium And 38th National Sickle Cell Disease Scientific Meeting

PR Newswire April 9, 2015

Mast Therapeutics Reports Fourth Quarter And Full Year 2014 Financial Results

PR Newswire March 24, 2015

Mast To Develop Vepoloxamer (MST-188) In Chronic Heart Failure

PR Newswire March 23, 2015

Mast Announces Results From Nonclinical Study Investigating Repeat Treatment With Vepoloxamer In Advanced Heart Failure

PR Newswire March 2, 2015

Mast Therapeutics To Present At Cowen And Company's 35th Annual Healthcare Conference On March 2nd

PR Newswire February 24, 2015

Mast Therapeutics Announces New Data Supporting Vepoloxamer In Embolic Stroke

PR Newswire February 11, 2015

Mast Therapeutics Announces Initiation Of Phase 2a Studies Of AIR001 In Patients With Heart Failure With Preserved Ejection Fraction (HFpEF)

PR Newswire February 4, 2015

Mast Therapeutics To Present At 17th Annual BIO CEO & Investor Conference On February 9th

PR Newswire February 3, 2015

Mast Therapeutics Announces Management Change

PR Newswire January 24, 2015

Mast Therapeutics To Present At 2015 Biotech Showcase Conference On January 12th

PR Newswire January 7, 2015

Mast Therapeutics Provides Update On Epic Study Enrollment And 2015 Milestones

PR Newswire January 5, 2015

Mast Therapeutics To Host Corporate Conference Call

PR Newswire December 30, 2014